The University of Plymouth is part of a groundbreaking project looking to find an effective treatment for the symptoms of long COVID.
It is estimated that over two million people in the UK, and more than 144 million globally, are living with long COVID and almost a quarter of sufferers have experienced symptoms such as extreme fatigue and breathlessness, palpitations, and brain fog for more than two years.
The
ERASE - long COVID trial, launched in September 2024 and led by the University of Derby, is the first of its kind in the UK, exploring whether anti-viral medications can be used as a treatment option for patients diagnosed with the condition.
The anti-viral medication being trialled is already used to treat people admitted to hospital with COVID-19, but as most people are not hospitalised with the condition, they do not have a way to access this medication.
This trial, involving 72 patients living with long COVID, will investigate whether it can alleviate some of the symptoms that people are living with.
The ERASE study is being managed by the
Peninsula Clinical Trials Unit (PenCTU) at the University of Plymouth.
It has almost two decades of experience managing clinical trials, including drug trials and other medical interventions, with the PenCTU team supporting researchers throughout the development and delivery of this new project.
They will also ensure the data generated through it are gathered and managed appropriately, so they can be used to inform the design of a larger future trial.
/University Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
